Leave a Nest Capital Makes Additional Investment in Rhelixa, Inc.

Leave a Nest Group has invested in Rhelixa, Inc. (Head office: Tokyo, Japan; Representative Director, CEO/CTO: Ryo Nakaki; hereinafter “Rhelixa”), through Leave a Nest Capital Co., Ltd.

A leading epigenome analysis company, Rhelixa carries the mission of “Decoding Life, Creating Future”. It analyzes omics data utilizing their proprietary technology and expertise, to dramatically improve the efficiency and accuracy of research and development.

In February 2024, Rhelixa and Leave a Nest launched the “Epiclock® Co-Creation Project” to establish a new concept of health different from calendar age, by measuring biological age based on the epigenome information and status of cells and tissues, thereby realizing a society without fear of aging.

Press Release: First of its kind in Japan, Leave a Nest and Rhelixa launch “Epiclock®︎ Co-Creation Project”

This time, Leave a Nest Group decided to make an additional investment driven by the desire to further accelerate the knowledge manufacturing industry that cultivate and propagate novel health concepts, as epitomized by the “Epiclock® Co-Creation Project”.

With this funding, Rhelixa aims to strengthen its financial foundation and to expand the Epiclock® business, leading to the creation and development of the anti-aging market in Japan and Asia, and accelerate the business toward realizing a society without fear of aging.

Moving forward, Leave a Nest Group will continue its efforts to create deep tech solutions addressing deep issues across various fields and contribute to global happiness.

About Rhelixa

• Company Name: Rhelixa, Inc. 
• Website: https://www.rhelixa.com/top-en/ 
• Head office: KDX Ginza East Building 5F, 3-7-2 Irifune, Chuo-ku, Tokyo, Japan
• CEO: Ryo Nakaki
• Established: February 2015